Impact of met-haemoglobin and oxidative stress on endothelial function in patients with transfusion dependent β-thalassemia.
EASIX
Malondialdehyde
Met-Hb
Oxidative stress
Transfusion depended β-thalassemia
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
05
08
2024
accepted:
30
09
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
Transfusion dependent β-thalassemia is a genetic blood disorder characterized by chronic anaemia. Blood transfusion is lifesaving but comes at a cost. Iron overload emerges as a prime culprit as a free radicals damage endothelial cells. Chronic anaemia further disrupts oxygen delivery, exacerbating the oxidative stress. Increased levels of met-haemoglobin and malondialdehyde compromise endothelial function. This research sheds light on the impact of met-haemoglobin and oxidative stress on endothelial function in 50 patients with transfusion dependent β-thalassemia major compared to 50 healthy individuals as control. Blood samples were collected & subjected to CBC, biochemical analysis including creatinine, ferritin, CRP, LDH, and HCV antibodies. Oxidative stress was assessed using met-haemoglobin & malondialdehyde. Endothelial dysfunction was evaluated by endothelial activation and stress index (EASIX). EASIX, met-haemoglobin and malondialdehyde were significantly increased in patients (1.44 ± 0.75, 2.07 ± 0.2, 4.8 ± 0.63; respectively) compared to the control (0.52 ± 0.24,0.88 ± 0.34,0.8 ± 0.34; respectively). Significant strong positive correlation was found between EASIX and met-haemoglobin, malondialdehyde, serum ferritin and CRP (P = 0.00, r = 0.904, P = 0.00, r = 0.948, P = 0.00, r = 0.772, P = 0.00, r = 0.971; respectively. Met-haemoglobin as well as EASIX should be routinely estimated to assess endothelial function especially before the decision of splenectomy. Antioxidant drugs should be supplemented.
Identifiants
pubmed: 39455629
doi: 10.1038/s41598-024-74930-3
pii: 10.1038/s41598-024-74930-3
doi:
Substances chimiques
Hemoglobins
0
Malondialdehyde
4Y8F71G49Q
Ferritins
9007-73-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25328Informations de copyright
© 2024. The Author(s).
Références
Shang, X. & Xu, X. Update in the genetics of thalassemia: What clinicians need to know. Best Pract. Res. Clin. Obstet. Gynaecol. 39, 3–15. https://doi.org/10.1016/j.bpobgyn.2016.10.012 (2017).
doi: 10.1016/j.bpobgyn.2016.10.012
pubmed: 27876354
Fibach, E. & Dana, M. Oxidative stress in β-thalassemia. Mol. Diagn. Ther. 23, 245–261. https://doi.org/10.1007/s40291-018-0373-5 (2019).
doi: 10.1007/s40291-018-0373-5
pubmed: 30484264
Abdolalian, M., Zarif, M. N. & Javan, M. The role of extracellular vesicles on the occurrence of clinical complications in β-thalassemia. Exp. Hematol. 127, 28–39. https://doi.org/10.1016/j.exphem.2023.08.009 (2023).
doi: 10.1016/j.exphem.2023.08.009
pubmed: 37652128
Higashi, Y. Roles of Oxidative Stress and Inflammation in Vascular Endothelial Dysfunction-Related Disease. Antioxidants (Basel) 11. https://doi.org/10.3390/antiox11101958 (2022).
Dimitrov, J. D., Roumenina, L. T., Perrella, G. & Rayes, J. Basic mechanisms of hemolysis-associated thrombo-inflammation and immune dysregulation. Arterioscler. Thromb. Vasc. Biol. 43, 1349–1361. https://doi.org/10.1161/atvbaha.123.318780 (2023).
doi: 10.1161/atvbaha.123.318780
pubmed: 37317847
Caprari, P. et al. Hemorheological profiles and chronic inflammation markers in transfusion-dependent and non-transfusion- dependent thalassemia. Front. Mol. Biosci. 9, 1108896. https://doi.org/10.3389/fmolb.2022.1108896 (2022).
doi: 10.3389/fmolb.2022.1108896
pubmed: 36699704
Joffre, J. & Hellman, J. Oxidative stress and endothelial dysfunction in sepsis and acute inflammation. Antioxid. Redox. Signal. 35, 1291–1307. https://doi.org/10.1089/ars.2021.0027 (2021).
doi: 10.1089/ars.2021.0027
pubmed: 33637016
Pallewar, T. S., Sharma, K., Sharma, S., Chandra, J. & Nangia, A. Endothelial activation markers in polytransfused children with beta thalassemia: Study from a Tertiary Care Centre in India. Indian J. Hematol. Blood Transfus. 38, 178–183. https://doi.org/10.1007/s12288-021-01471-4 (2022).
doi: 10.1007/s12288-021-01471-4
pubmed: 35125727
Liu, X. & Spolarics, Z. Methemoglobin is a potent activator of endothelial cells by stimulating IL-6 and IL-8 production and E-selectin membrane expression. Am. J. Physiol. Cell Physiol. 285, C1036-1046. https://doi.org/10.1152/ajpcell.00164.2003 (2003).
doi: 10.1152/ajpcell.00164.2003
pubmed: 12839837
Hirsch, R. E., Sibmooh, N., Fucharoen, S. & Friedman, J. M. HbE/β-thalassemia and oxidative stress: The key to pathophysiological mechanisms and novel therapeutics. Antioxid. Redox. Signal 26, 794–813. https://doi.org/10.1089/ars.2016.6806 (2017).
doi: 10.1089/ars.2016.6806
pubmed: 27650096
pmcid: 5421591
Bamm, V. V., Henein, M. E. L., Sproul, S. L. J., Lanthier, D. K. & Harauz, G. Potential role of ferric hemoglobin in MS pathogenesis: Effects of oxidative stress and extracellular methemoglobin or its degradation products on myelin components. Free Radic. Biol. Med. 112, 494–503. https://doi.org/10.1016/j.freeradbiomed.2017.08.022 (2017).
doi: 10.1016/j.freeradbiomed.2017.08.022
pubmed: 28863941
Pagan, L. U., Gomes, M. J., Martinez, P. F. & Okoshi, M. P. Oxidative stress and heart failure: Mechanisms, signalling pathways, and therapeutics. Oxid. Med. Cell. Longev. 2022, 9829505. https://doi.org/10.1155/2022/9829505 (2022).
doi: 10.1155/2022/9829505
pubmed: 35464761
pmcid: 9023191
Shaito, A. et al. Oxidative stress-induced endothelial dysfunction in cardiovascular diseases. Front. Biosci. 27, 105. https://doi.org/10.31083/j.fbl2703105 (2022).
Ali, S. et al. Current status of beta-thalassemia and its treatment strategies. Mol. Genet. Genomic. Med. 9, e1788. https://doi.org/10.1002/mgg3.1788 (2021).
doi: 10.1002/mgg3.1788
pubmed: 34738740
pmcid: 8683628
Chennupati, R. et al. Chronic anemia is associated with systemic endothelial dysfunction. Front. Cardiovasc. Med. 10, 1099069. https://doi.org/10.3389/fcvm.2023.1099069 (2023).
doi: 10.3389/fcvm.2023.1099069
pubmed: 37234375
pmcid: 10205985
Meegan, J. E., Bastarache, J. A. & Ware, L. B. Toxic effects of cell-free hemoglobin on the microvascular endothelium: Implications for pulmonary and nonpulmonary organ dysfunction. Am. J. Physiol. Lung Cell Mol. Physiol. 321, L429-l439. https://doi.org/10.1152/ajplung.00018.2021 (2021).
doi: 10.1152/ajplung.00018.2021
pubmed: 34009034
pmcid: 8526348
Cyr, A. R., Huckaby, L. V., Shiva, S. S. & Zuckerbraun, B. S. Nitric oxide and endothelial dysfunction. Crit. Care Clin. 36, 307–321. https://doi.org/10.1016/j.ccc.2019.12.009 (2020).
doi: 10.1016/j.ccc.2019.12.009
pubmed: 32172815
pmcid: 9015729
Lal, A. Challenges in chronic transfusion for patients with thalassemia. Hematol. Am. Soc. Hematol. Educ. Program. 2020, 160–166. https://doi.org/10.1182/hematology.2020000102 (2020).
doi: 10.1182/hematology.2020000102
Sposi, N. M. Beta Thalassemia; Oxidative Stress and Iron Overload in β-Thalassemia: An Overview (2019).
Sovira, N. et al. Effects of α-tocopherol on hemolysis and oxidative stress markers on red blood cells in β-thalassemia major. Clin. Exp. Pediatr. 63, 314–320. https://doi.org/10.3345/cep.2019.00542 (2020).
doi: 10.3345/cep.2019.00542
pubmed: 32668823
pmcid: 7402984
Barclay, J. A., Ziemba, S. E. & Ibrahim, R. B. Dapsone-induced methemoglobinemia: A primer for clinicians. Ann. Pharmacother. 45, 1103–1115. https://doi.org/10.1345/aph.1Q139 (2011).
doi: 10.1345/aph.1Q139
pubmed: 21852596
Tandon, V. R. et al. Drug-induced diseases (DIDs): An experience of a tertiary care teaching hospital from India. Indian J. Med. Res. 142, 33–39. https://doi.org/10.4103/0971-5916.162093 (2015).
doi: 10.4103/0971-5916.162093
pubmed: 26261164
pmcid: 4557247
Varma, A. et al. Endothelial Activation and Stress Index (EASIX) at admission predicts fluid overload in recipients of allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 26, 1013–1020. https://doi.org/10.1016/j.bbmt.2020.01.028 (2020).
doi: 10.1016/j.bbmt.2020.01.028
pubmed: 32045652
Feissal Rabie, M. A., Gaber, M. H., Soula, M. A. & Masoud, I. M. Endothelail and stress index as one of new prognostic determinants of COVID- 19 severity. Afro-Egypt. J. Infecti. Endemic Dis. 13, 101–113. https://doi.org/10.21608/aeji.2023.206428.1287 (2023).
Jameson, J. L. et al. in Harrison’s Principles of Internal Medicine, 20e Ch. 299, e1-e8 (McGraw-Hill Education, 2018).
Kowalczyk, P. et al. Mitochondrial oxidative stress—A causative factor and therapeutic target in many diseases. Int. J. Mol .Sci. 22. https://doi.org/10.3390/ijms222413384 (2021).
Ayyash, H. & Sirdah, M. Hematological and biochemical evaluation of β-thalassemia major (βTM) patients in Gaza Strip: A cross-sectional study. Int. J. Health Sci. 12, 18–24 (2018).
Aldwaik, R. et al. Health status of patients with β-thalassemia in the West Bank: A retrospective-cohort study. Front. Med . 8, 788758. https://doi.org/10.3389/fmed.2021.788758 (2021).
Solangi, D. A. et al. Blood chemistry (hematology) of transfusion dependent Beta thalassemia patients at hyderabad and adjoining areas. 2018 19, 5. https://doi.org/10.21743/pjaec/2018.06.09 (2018).
Sande, C. et al. Impact of splenectomy on postsurgical platelet count. Am. J. Clin. Pathol. 152, S24–S25. https://doi.org/10.1093/ajcp/aqz112.047 (2019).
doi: 10.1093/ajcp/aqz112.047
Basu, D., Adhya, D. G., Sinha, R. & Chakravorty, N. Role of malonaldehyde as a surrogate biomarker for iron overload in the β-thalassemia patient: A systematic meta-analysis. Adv. Redox. Res. 3, 100017. https://doi.org/10.1016/j.arres.2021.100017 (2021).
doi: 10.1016/j.arres.2021.100017
Neaimy, K. S. A., Alkhyatt, M. M. & Jarjess, I. A. New insights of oxidative stress and thalassemia may lead to antioxidant therapy. Pharmacognosy J. (2024).
Al-Hakeim, H. K., Auda, F. M. & Ali, B. M. Lack of correlation between non-labile iron parameters, total carbonyl and malondialdehyde in major thalassemia. J. Clin. Biochem. Nutr. 55, 203–206. https://doi.org/10.3164/jcbn.14-24 (2014).
doi: 10.3164/jcbn.14-24
pubmed: 25411527
pmcid: 4227823
Fatima, T. et al. Oxidative stress in Beta-thalassemia Patients: Role of enzymatic and non-enzymatic modulators. Protein Pept. Lett. 30, 1030–1037. https://doi.org/10.2174/0109298665246270231020062048 (2023).
doi: 10.2174/0109298665246270231020062048
pubmed: 37953620
Jarisch, A. et al. Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation. Eur. J. Haematol. 101, 791–797. https://doi.org/10.1111/ejh.13169 (2018).
doi: 10.1111/ejh.13169
pubmed: 30187571
Shah, F. et al. Relationship between serum ferritin and outcomes in β-Thalassemia: A systematic literature review. J. Clin. Med. 11. https://doi.org/10.3390/jcm11154448 (2022).
Balbaa, O. A., Kamel, M. A., Salem, K. S. & Sadek, N. A. Impact of haptoglobin gene polymorphism on phenotypic variability in β-thalassemia patients: relation to iron overload and oxidative stress. Afro-Egypt. J. Infect. Endemic Dis. 13, 181–189. https://doi.org/10.21608/aeji.2023.220501.1299 (2023).
Garbowski, M. W. et al. Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia. Am. J. Hematol. 99, 182–192. https://doi.org/10.1002/ajh.27102 (2024).
doi: 10.1002/ajh.27102
pubmed: 37782758
Luft, T. et al. EASIX in patients with acute graft-versus-host disease: A retrospective cohort analysis. Lancet Haematol. 4, e414–e423. https://doi.org/10.1016/s2352-3026(17)30108-4 (2017).
doi: 10.1016/s2352-3026(17)30108-4
pubmed: 28733186
Scioli, M. G. et al. Oxidative stress and new pathogenetic mechanisms in endothelial dysfunction: Potential diagnostic biomarkers and therapeutic targets. J. Clin. Med. 9. https://doi.org/10.3390/jcm9061995 (2020).
Rebbani, K. & Tsukiyama-Kohara, K. HCV-induced oxidative stress: Battlefield-winning strategy. Oxid. Med. Cell Longev. 2016, 7425628. https://doi.org/10.1155/2016/7425628 (2016).
doi: 10.1155/2016/7425628
pubmed: 27293514
pmcid: 4880679
Almaeen, A. H. et al. Oxidative stress, immunological and cellular hypoxia biomarkers in hepatitis C treatment-naïve and cirrhotic patients. Arch. Med. Sci. 17, 368–375. https://doi.org/10.5114/aoms.2019.91451 (2021).
doi: 10.5114/aoms.2019.91451
pubmed: 33747272
Hanafy, A. S., Basha, M. A. K. & Wadea, F. M. Novel markers of endothelial dysfunction in hepatitis C virus-related cirrhosis: More than a mere prediction of esophageal varices. World J. Hepatol. 12, 850–862. https://doi.org/10.4254/wjh.v12.i10.850 (2020).
doi: 10.4254/wjh.v12.i10.850
pubmed: 33200022
pmcid: 7643206
Farmakis, D. et al. 2021 Thalassaemia International Federation Guidelines for the management of transfusion-dependent thalassemia. Hemasphere 6, e732. https://doi.org/10.1097/hs9.0000000000000732 (2022).
doi: 10.1097/hs9.0000000000000732
pubmed: 35928543
pmcid: 9345633
Rawi, S. & Wu, G. Y. Pathogenesis of thrombocytopenia in chronic HCV infection: A review. J. Clin. Transl. Hepatol. 8, 184–191. https://doi.org/10.14218/jcth.2020.00007 (2020).
Kedia, S. et al. Benign and malignant hematological manifestations of chronic hepatitis C virus infection. Int. J. Prev. Med. 5, S179-192 (2014).
pubmed: 26622988
pmcid: 4635414
Abozeid, F., Shaaban, Y., Elbogdady, M. & Jamal, E. Evaluation of hepatic toxicity in autoimmune hemolytic anemia (AIHA) and Evans syndrome patients: A single-center Egyptian study. Egypt. J. Internal Med. 36, 22. https://doi.org/10.1186/s43162-024-00279-8 (2024).
doi: 10.1186/s43162-024-00279-8
Kedia, S. et al. Splenectomy in cirrhosis with hypersplenism: Improvement in cytopenias, Child’s status and institution of specific treatment for hepatitis C with success. Ann. Hepatol. 11, 921–929 (2012).
doi: 10.1016/S1665-2681(19)31419-X
pubmed: 23109457
Akhtari, M., Curtis, B. & Waller, E. K. Autoimmune neutropenia in adults. Autoimmun. Rev. 9, 62–66. https://doi.org/10.1016/j.autrev.2009.03.006 (2009).
doi: 10.1016/j.autrev.2009.03.006
pubmed: 19293004
Abou El Azm, A. R. et al. Correlation of viral load with bone marrow and hematological changes in pale patients with chronic hepatitis C virus. Arch. Virol. 157, 1579–1586. https://doi.org/10.1007/s00705-012-1321-z (2012).
Aref, S. et al. Neutrophil apoptosis in neutropenic patients with hepatitis C infection: Role of Caspases 3, 10, and GM-CSF. Indian J. Hematol. Blood Transfus. 27, 81–87. https://doi.org/10.1007/s12288-011-0067-1 (2011).
doi: 10.1007/s12288-011-0067-1
pubmed: 22654297
pmcid: 3136665
Sulkowski, M. S. Management of the hematologic complications of hepatitis C therapy. Clin. Liver Dis. 9, 601–616, vi. https://doi.org/10.1016/j.cld.2005.07.007 (2005).
Origa, R. β-Thalassemia. Genet. Med. 19, 609–619. https://doi.org/10.1038/gim.2016.173 (2017).
doi: 10.1038/gim.2016.173
pubmed: 27811859
Peng, W. et al. Prognostic value of the platelet to lymphocyte ratio change in liver cancer. J. Surg. Res. 194, 464–470. https://doi.org/10.1016/j.jss.2014.12.021 (2015).
doi: 10.1016/j.jss.2014.12.021
pubmed: 25577142
Meng, X. et al. The platelet-to-lymphocyte ratio, superior to the neutrophil-to-lymphocyte ratio, correlates with hepatitis C virus infection. Int. J. Infect. Dis. 45, 72–77. https://doi.org/10.1016/j.ijid.2016.02.025 (2016).
doi: 10.1016/j.ijid.2016.02.025
pubmed: 26948479
Sharma, A., Easow Mathew, M. & Puri, L. Splenectomy for people with thalassaemia major or intermedia. Cochrane Database Syst. Rev. 9, Cd010517. https://doi.org/10.1002/14651858.CD010517.pub3 (2019).
Talaat, A., Ismail, N. A., Habib, S. A. & Orban, H. A. A. Role of iron chelators, hydroxyurea, and splenectomy on serum total antioxidant capacity in β-thalassemia. Open Access Macedonian J. Med. Sci. (2020).
Crary, S. E. & Buchanan, G. R. Vascular complications after splenectomy for hematologic disorders. Blood 114, 2861–2868. https://doi.org/10.1182/blood-2009-04-210112 (2009).
doi: 10.1182/blood-2009-04-210112
pubmed: 19636061
pmcid: 2756197
Aggeli, C. et al. Endothelial dysfunction and inflammatory process in transfusion-dependent patients with beta-thalassemia major. Int. J. Cardiol. 105, 80–84 (2005).
doi: 10.1016/j.ijcard.2004.12.025
pubmed: 16207549
Breuer, W. et al. Non-transferrin bound iron in Thalassemia: Differential detection of redox active forms in children and older patients. Am. J. Hematol. 87, 55–61. https://doi.org/10.1002/ajh.22203 (2012).
doi: 10.1002/ajh.22203
pubmed: 22125177
Ajith, T. A. & Jayakumar, T. G. Mitochondria-targeted agents: Future perspectives of mitochondrial pharmaceutics in cardiovascular diseases. World J. Cardiol. 6, 1091–1099. https://doi.org/10.4330/wjc.v6.i10.1091 (2014).
doi: 10.4330/wjc.v6.i10.1091
pubmed: 25349653
pmcid: 4209435
Incalza, M. A. et al. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul. Pharmacol. 100, 1–19. https://doi.org/10.1016/j.vph.2017.05.005 (2018).
doi: 10.1016/j.vph.2017.05.005
pubmed: 28579545
Kedar, P. S., Gupta, V., Warang, P., Chiddarwar, A. & Madkaikar, M. Novel mutation (R192C) in CYB5R3 gene causing NADH-cytochrome b5 reductase deficiency in eight Indian patients associated with autosomal recessive congenital methemoglobinemia type-I. Hematology 23, 567–573. https://doi.org/10.1080/10245332.2018.1444920 (2018).
doi: 10.1080/10245332.2018.1444920
pubmed: 29482478
Haghpanah, S. et al. The effect of vitamin E and N-acetyl cysteine on oxidative status and hemoglobin level in transfusion-dependent thalassemia patients: A systematic review and meta-analysis. Iran. J. Blood Cancer (2023).